Gensight Biologics S.a annual revenue
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Revenue Growth & History (SIGHT)
Gensight Biologics S.a reported €1,000 in revenue for fiscal 2025, a decrease of 99.93% from the previous fiscal year.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €1,000 | −€1.5M | −99.93% |
| 2024 | 2024-12-31 | €1.5M | €233,000 | +18.39% |
| 2023 | 2023-12-31 | €1.3M | −€1.3M | −50.93% |
| 2022 | 2022-12-31 | €2.6M | −€2.7M | −51.06% |
| 2021 | 2021-12-31 | €5.3M | €882,000 | +20.07% |
| 2020 | 2020-12-31 | €4.4M | — | — |
Gensight Biologics S.a revenue growth trends
Over the last five reported fiscal years, revenue declined from €4.4M to €1,000, a compound annual decline of 81.32%.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...